Effects of linagliptin and liraglutide on glucose-and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro

Acta Pharmacologica Sinica

Volumn 37, Issue 10, 2016, Pages 1349-1358

  Wang, Xian Wei ^a,b   Zhang, Fen Xi ^c   Yang, Fen ^a   Ding, Zu Feng ^b   Agarwal, Nidhi ^b   Guo, Zhi Kun ^a   Mehta, Jawahar L ^b  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c HENAN NORMAL UNIVERSITY   (China)

Author keywords

angiotensin II; cardiac fibroblast; Cardiac remodeling; collagen formation; cytoskeleton organization; glucose; linagliptin; liraglutide

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANGIOTENSIN II; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; F ACTIN; FIBRONECTIN; GLUCOSE; I KAPPA B; JSH 23; LINAGLIPTIN; LIRAGLUTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHALLOIDIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; ACTIN; COLLAGEN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CYTOSKELETON; DEGRADATION; DRUG EFFECT; HEART FIBROBLAST; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; WESTERN BLOTTING; AGONISTS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CARDIAC MUSCLE; CYTOLOGY; DRUG EFFECTS; FIBROBLAST; METABOLISM; ULTRASTRUCTURE;

ACTINS; ANGIOTENSIN II; ANIMALS; COLLAGEN; CYTOSKELETON; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FIBROBLASTS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; LINAGLIPTIN; LIRAGLUTIDE; MICE; MICE, INBRED C57BL; MYOCARDIUM;

EID: 84989888013     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2016.72     Document Type: Article

References (33)

1. Lee TI, Kao YH, Chen YC, Huang JH, Hsu MI, Chen YJ. The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes. Int J Cardiol 2013; 168: 5390-5.
2. Zhao Y, Yang L, Zhou Z. Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs. J Diabetes 2014; 6: 21-9.
3. Lenski M, Kazakov A, Marx N, Böhm M, Laufs U. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol 2011; 51: 906-18.
4. Picatoste B, Ramírez E, Caro-Vadillo A, Iborra C, Ares-Carrasco S, Egido J, et al. Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS One 2013; 8: e78330.
5. Connelly KA, Zhang Y, Advani A, Advani SL, Thai K, Yuen DA, et al. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes. Cardiovasc Ther 2013; 31: 259-67.
6. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-ananlysis of a phase 3 programme. Cardiovasc Diabetol 2012; 11: 3.
7. Nogueira KC, Furtado M, Fukui RT, Correia MR, Dos Santos RF, Andrade JL, et al. Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor-a pilot study. Diabetol Metab Syndr 2014; 6: 103.
8. Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol 2013; 167: 87-93.
9. Chinda K, Palee S, Surinkaew S, Phornphtkul M, Chattipakorn S, Chattipakorn N. Cardioprotective effect of dipeptidyl peptidae-4 inhibitor during ischemia-reperfusion injury. Int J Cardiol 2013; 167: 451-7.
10. Wang X, Lu J, Khaidakov M, Mitra S, Ding Z, Raina S, et al. Aspirin suppresses cardiac fibroblast proliferation and collagen formation through downregulation of angiotensin type 1 receptor transcription. Toxicol Appl Pharmacol 2012; 259: 346-54.
11. Wang X, Khaidakov M, Ding Z, Mercanti F, Mehta JL. LOX-1 in the maintenance of cytoskeleton and proliferation in senescent cardiac fibroblasts. J Mol Cell Cardiol 2013; 60: 184-90.
12. Tang M, Zhang W, Lin H, Jiang H, Dai H, Zhang Y. High glucose promotes the production of collagen types I and III by cardiac fibroblasts through a pathway dependent on extracellular-signal-regulated kinase 1/2. Mol Cell Biochem 2007; 301: 109-14.
13. Huang J, Siragy HM. Regulation of (pro) renin receptor expression by glucose-induced mitogen-activated protein kinase, nuclear factor-kappaB, and activator protein-1 signaling pathways. Endocrinology 2010; 151: 3317-25.
14. Madhyastha R, Madhyastha H, Pengam Y, Nakajima Y, Omura S, Maruyama M. NFkappaB activation is essential for miR-21 induction by TGF1 in high glucose conditions. Biochem Biophys Res Commun 2014; 451: 615-21.
15. Wang LP, Wang Y, Zhao LM, Li GR, Deng XL. Angiotensin II upregulates KCa3.1 channels and stimulates cell proliferation in rat cardiac fibroblasts. Biochem Pharmacol 2013; 85: 1486-94.
16. Choi C, Helfman DM. The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2. Oncogene 2013; 33: 3669-76.
17. Cortez DM, Feldman MD, Mummidi S, Valente AJ, Steffensen B, Vincenti M, et al. IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK-and ERK1/2-dependent C/EBP-beta, NF-kappaB, and AP-1 activation. Am J Physiol Heart Circ Physiol 2007; 293: H3356-65.
18. Fiaschi T, Magherini F, Gamberi T, Lucchese G, Faggian G, Modesti A, et al. Hyperglycemia and angiotensin II cooperate to enhance collagen I deposition by cardiac fibroblasts through a ROS-STAT3-dependent mechanism. Biochim Biophys Acta 2014; 1843: 2603-10.
19. Copaja M, Venegas D, Aranguiz P, Canales J, Vivar R, Avalos Y, et al. Simvastatin disrupts cytoskeleton and decreases cardiac fibroblast adhesion, migration and viability. Toxicology 2012; 294: 42-9.
20. Schram K, Granguly R, No EK, Fang X, Thong FS, Sweeney G. Regulation of MT1-MMP and MMP-2 by leptin in cardiac fibroblasts involves Rho/ROCK-dependent actin cytoskeletal reorganization and leads to enhanced cell migration. Endocrinology 2011; 152: 2037-47.
21. Sassoli C, Chellini F, Pini A, Tani A, Nistri S, Nosi D, et al. Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-/Smad3 signaling. PLoS One 2013; 8: e63896.
22. Lee TM, Lin SZ, Chang NC. Membrane ER attenuates myocardial fibrosis via RhoA/ROCK-mediated actin remodeling in ovariectomized female infarcted rats. J Mol Med (Berl) 2014; 92: 43-51.
23. Shi D, Li X, Chen H, Che N, Zhou S, Lu Z, et al. High level of reactive oxygen species impaired mesenchymal stem cell migration via overpolymerization of F-actin cytoskeleton in systemic lupus erythematosus. Pathol Biol (Paris) 2014; 62: 382-90.
24. Surma M, Handy C, Chang J, Kapur R, Wei L, Shi J. ROCK1 deficiency enhances protective effects of antioxidants against apoptosis and cell detachment. PLoS One 2014; 9: e90758.
25. Kröller-Schön S, Knorr M, Hausding M, Oelze M, Schuff A, Schell R, et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 2012; 96: 140-9.
26. Batchuluun B, Inoguchi T, Sonoda N, Sasaki S, Inoue T, Fujimura Y, et al. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. Atherosclerosis 2014; 232: 156-64.
27. Thakur S, Li L, Gupta S. NF-B-mediated integrin-linked kinase regulation in angiotensin II-induced pro-fibrotic process in cardiac fibroblasts. Life Sci 2014; 107: 68-75.
28. Tang M, Zhong M, Shang Y, Lin H, Deng J, Jiang H, et al. Differential regulation of collagen type I and III expression in cardiac fibroblasts by AGEs through TRB3/MAPK signaling pathway. Cell Mol Life Sci 2008; 65: 2924-32.
29. Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RA, Katovich MJ, et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 2011; 96: 287-94.
30. Ares-Carrasco S, Picatoste B, Benito-Martin A, Zubiri I, Sanz AB, Sánchez-Ninõ MD, et al. Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. Am J Physiol Heart Circ Physiol 2009; 297: H2109-19.
31. Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004; 43: 1481-8.
32. Villarreal F, Epperson SA, Ramirez-Sanchez I, Yamazaki KG, Brunton LL. Regulation of cardiac fibroblast collagen synthesis by adenosine: roles for Epac and PI3K. Am J Physiol Cell Physiol 2009; 296: C1178-84.
33. Nakano H, Nakajima A, Sakon-Komazawa S, Piao JH, Xue X, Okumura K. Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ 2006; 13: 730-7.